Advance - movement forward
- Authors: Petunina NA1, Petunina N1
-
Affiliations:
- Issue: No 3 (2010)
- Pages: 32-38
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278235
- ID: 278235
Cite item
Full Text
Abstract
The article is dedicated to the problems of type 2 diabetes mellitus. New results of ADVANCE study, related to glycemic control and prediction of cardiovascular risk in patients with diabetes mellitus are presented. Use of gliclazide MR in a dose of 120 mg lead to reduction of glycosylated hemoglobin to the target level regardless of the clinical characteristics of patients and the previously prescribed treatment. Based on data of ADVANCE study, new model for calculating the cardiovascular risk was suggested. This model is based on such factors as sex, patient's age at diagnosis, duration of diabetes, blood pressure and pulse pressure levels, albumin/creatinine ratio, etc.
References
- Chalmers J, Zoungas S, Ninomiya T, et al. New results from ADVANCE. IDF Congress Invited Talk. Montreal, Canada 22 October 2009.
- The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
- Turnbull F, Abraira C, Anderson R, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009.
- Schramm TK. Eur Heart J 2009;30:304. Abstract ESC Congress 2009.
- Khalangot M, Tronko M, Kravchenko V, et al. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study Diabetes Res Clin Pract 2009 Sep 29.
- Zoungas S, Patel A, Neal B, et al. ADVANCE-ON: a post-trial observational study. Oral presentation, IDF Congress, 21 October 2009. Montreal, Canada.
- Kengne AP, Patel A, Colagiuri S, et al. Derivation of the ADVANCE models for predicting the risk of major cardiovascular disease in people with diabetes. Oral presentation, IDF Congress, 20 October 2009. Montreal, Canada.
Supplementary files
